Amivantamab

(Rybrevant)

Amivantamab

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 350 mg/7 mL)
Drug ClassMonoclonal antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Rybrevant (amivantamab-vmjw) Prescribing Information.2022Janssen Biotech, Inc., Horsham, PA

Systematic Reviews / Meta-Analyses